The Carve-Out Question: When Separating Pharmacy Makes Sense
A decision framework for self-funded employers evaluating pharmacy carve-out vs. bundled administration
Ask your PBM about carving out pharmacy. I have watched the reaction enough times to predict it. They will tell you it is disruptive, complex, risky. What they will not tell you is that bundling is how they control your data, your rebate flow, and your negotiating position at renewal.
We walked a client through this evaluation last year. During the renewal meeting, the employer asked a direct question: what would our pharmacy pricing look like if we carved out? The room went quiet. The PBM representative pivoted to “integration value” and “administrative simplicity.” The actual pricing comparison never happened. That employer renewed bundled, without ever seeing what the market would offer for their pharmacy benefit as a standalone contract.
That pattern repeats constantly. Most employers never chose their current pharmacy structure. They inherited it. Bundled pharmacy came with the medical package. It was part of the deal. And the PBM has every financial reason to make sure that default goes unexamined.
Why most employers never look at this
Inertia. That is the simplest answer. Nobody questioned the arrangement because nobody presented an alternative.
The second reason is messaging. PBMs and their bundled partners position the arrangement as the simpler, safer, more integrated option. And to be fair, there is truth in that. One vendor relationship, integrated reporting, a single point of contact. For employers with lean benefits teams, that simplicity has genuine value.
But simplicity and value are not the same thing. We review hundreds of PBM contracts each year. Bundled arrangements consistently show less pricing transparency, less rebate visibility, and less competitive pressure than carved-out alternatives. That does not mean bundled is always worse. It means the employers who never compare are the ones most likely to be overpaying.
When staying bundled makes sense
I want to be honest about this. Bundled arrangements work well in certain situations.
If your benefits team has limited bandwidth, the administrative simplicity of a single vendor relationship may outweigh pricing differences. If benchmarking confirms your current pharmacy pricing is competitive with market rates, the case for disruption weakens. If pharmacy-medical data integration drives real value for your care management programs, native data sharing across a single platform is a genuine advantage.
The key word is “if.” These conditions should be verified, not assumed. Most employers assume their bundled pricing is competitive without ever benchmarking it.
When carving out makes sense
Carved-out arrangements create competitive pressure that bundled arrangements usually lack. When you negotiate a standalone PBM contract, multiple PBMs compete for your business. Bundled arrangements do not generate that same pricing tension because the pharmacy is folded into a larger relationship.
Beyond pricing, carved-out arrangements typically give you greater transparency into rebate flows, drug pricing, and performance guarantees. Bundled arrangements can obscure pharmacy economics within the broader carrier relationship. It gets harder to isolate what you are actually paying for pharmacy.
There is also a negotiating angle that often gets overlooked. The ability to carve out creates power even in your medical discussions. PBMs value the bundled relationship. The credible threat of separation influences terms across the board. The best brokers know this and use the evaluation strategically, even when the recommendation ends up being to stay bundled.
The decision scorecard
I walked a client through this evaluation a couple years ago, and the scorecard made the conversation much more productive than the usual back-and-forth about “what feels right.” Rate each of the following ten factors on a 1 to 5 scale based on your current situation. Higher scores favor carve-out. Lower scores favor staying bundled.
Pricing Transparency. Can you verify your PBM’s pricing against market benchmarks? Score 1 (Favor Bundled): Full transparency, competitive pricing. Score 5 (Favor Carve-Out): Limited visibility, unable to benchmark.
Rebate Flow. Do you receive and can you verify rebate passthrough? Score 1 (Favor Bundled): Clear passthrough, auditable. Score 5 (Favor Carve-Out): Opaque, “competitive” language, no audit rights.
Data Access. Do you have full, timely access to claims data? Score 1 (Favor Bundled): Complete data, flexible reporting. Score 5 (Favor Carve-Out): Limited data, PBM-controlled reporting.
Contract Flexibility. Can you negotiate pharmacy terms independently? Score 1 (Favor Bundled): Full negotiation flexibility. Score 5 (Favor Carve-Out): Terms tied to medical bundle, limited flexibility.
Specialty Management. Are you satisfied with specialty pharmacy routing and cost management? Score 1 (Favor Bundled): Strong specialty performance. Score 5 (Favor Carve-Out): Specialty costs growing, limited control.
Clinical Programs. Do clinical programs (PA, step therapy, MTM) deliver measurable value? Score 1 (Favor Bundled): Documented ROI on clinical programs. Score 5 (Favor Carve-Out): Programs exist on paper, no outcomes data.
Renewal Position. At renewal, do you have competitive alternatives? Score 1 (Favor Bundled): Multiple competitive options. Score 5 (Favor Carve-Out): Locked in, high switching costs.
Internal Capacity. Does your team have bandwidth to manage a separate PBM relationship? Score 1 (Favor Bundled): Dedicated benefits team, broker support. Score 5 (Favor Carve-Out): Lean team, limited pharmacy expertise.
Plan Size. Is your plan large enough to attract competitive carved-out pricing? Score 1 (Favor Bundled): 5,000+ lives, attractive to PBM market. Score 5 (Favor Carve-Out): Under 1,000 lives, limited market interest.
Advisory Support. Does your advisory team include PBM-specific expertise for a carved-out evaluation? Score 1 (Favor Bundled): PBM-specialized consultant on the team. Score 5 (Favor Carve-Out): Team would benefit from adding pharmacy-specific support.
A total score of 10 to 20 suggests staying bundled and focusing on improving transparency within the current arrangement. A score of 21 to 30 warrants further evaluation; request a parallel carved-out RFP to compare. A score of 31 to 40 is a strong case for carve-out and a formal evaluation process. A score of 41 to 50 suggests carve-out is likely the better structure and transition planning should be a priority.
Illustrative example for educational purposes. Actual evaluation criteria vary by plan.
No scorecard replaces a thorough financial analysis. But it forces the right questions and tells you whether the evaluation warrants deeper work.
Implementation realities
If the scorecard points toward carve-out, the decision is only the beginning.
Review your medical contract for provisions that address pharmacy. Some medical contracts include pricing adjustments when pharmacy is carved out, and that is reasonable from the carrier’s perspective since the bundled pricing assumed a combined relationship. Some include notice requirements. Your broker can help you identify these provisions before you start the process. Ensure data portability so you can access historical pharmacy data through the transition. Allow sufficient time for member communication, pharmacy network mapping, and system implementation.
Prior authorization transfer from the old PBM to the new one is the single most common implementation failure we see. Members who had active PAs suddenly need new approvals, and if nobody plans for that handoff, you get a wave of disrupted therapy and angry phone calls in the first two weeks. It requires specific planning.
The transition deserves as much rigor as the decision itself. Employers who invest in the analysis but rush the implementation often see problems that erode the projected savings.
What we advise
The carve-out decision should be made on data, not assumptions or vendor preferences. Bundled arrangements fold pharmacy economics into a larger carrier relationship where it is harder to see what you are paying, how it compares, and where margin lives. Carving out does not automatically fix that, but it often makes the economics visible.
Some employers get excellent results bundled. Others do better carved out. The answer depends on your specific circumstances, and a good broker or consultant can help you structure the evaluation.
The most expensive structural decision in pharmacy benefits is the one you never made.
Have you evaluated carve-out for your plan? If you went through the process and learned something unexpected, leave a comment below. If this framework is useful, share it with your broker or benefits team.
For the full protective contract language on termination notice, data transfer, and specialty routing provisions, see our free PBM Contract Language Library: https://benefitblindspots.substack.com/p/pbm-contract-language-library. Updated quarterly from patterns we see in client contract reviews.
Questions on the carve-out decision? Reach out at team@rxbs.org.
If you are not yet subscribed to Benefit Blind Spots, subscribe to receive the weekly analysis and Thursday field notes.